Dynamic profiling of immune microenvironment during anti-PD-1 immunotherapy for head and neck squamous cell carcinoma: The IPRICE study

Immune checkpoint inhibitors of programmed cell death protein 1 (PD-1) represent a signifcant break‑ through in treating head and neck squamous cell carcinoma (HNSCC), with long-lasting responses and prolonged survival observed in frst- and second-line therapy. However, this is observed in